Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.
Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.
复制标题
DOI：
10.1016/j.cllc.2011.05.001
复制
发表时间：
2012-01
影响因子：
3.6
通讯作者：
Loo BW
中科院分区：
文献类型：
--
作者：
Lee P;Bazan JG;Lavori PW;Weerasuriya DK;Quon A;Le QT;Wakelee HA;Graves EE;Loo BW
Fluroine-18 flurodeoxyglucose positron emission tomography（FDG-PET）成像被认为是非小细胞肺癌（NSCLC）的标准。对61例NSCLC患者的回顾性分析显示，较高的FDG-PET代谢肿瘤体积预示着总体和明确治疗的患者亚组的预后较差。氟-18氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）成像已迅速成为肺癌患者分期的标准治疗方法。我们评估了代谢肿瘤体积（MTV）的预后价值，这是FDG-PET成像上肿瘤负荷的一种测量方法，用于确定性治疗的非小细胞肺癌（NSCLC）患者。一项回顾性审查确定了61例接受FDG-PET成像进行治疗前分期的NSCLC患者。在PET扫描上半自动地分割代谢活跃的肿瘤区域以计算全身MTV。我们确定了整个队列和明确治疗的亚组中总生存期（OS）和无进展生存期（PFS）与MTV的关系。整个队列的估计中位PFS和OS分别为11.1个月和18.9个月。MTV越高，OS（P = 0.00075）和PFS（P = 0.00077）越差。对于明确治疗的患者，当MTV作为高于或低于中位数的二元值进行分析时，2年PFS为60% vs 39.7%（中位PFS 34.9 vs. 11.9个月）和2年OS分别为79.7% vs. 33.3%（中位OS 41.9 vs. 18.9个月）（PFS的对数秩P = 0.12，OS的P = 0.066）。当MTV作为连续变量进行分析时，多变量考克斯比例风险分析显示，在控制已知预后变量后，随着MTV的增加，PFS（风险比[HR] = 1.31; P = 0.12）和OS（HR = 1.53; P = 0.018）有变差的趋势。通过MTV评估的肿瘤负荷产生了确定性治疗的NSCLC患者中超出既定预后因素的生存期预后信息。
Fluroine-18 flurodeoxyglucose positron emission tomography (FDG-PET) imaging is considered standard for Non-Small Cell Lung Cancer (NSCLC). A retrospective review of 61 patients with NSCLC showed that higher FDG-PET metabolic tumor volume portended worse outcomes overall and in a subset of patients treated definitively. Fluorine-18 flurodeoxyglucose positron emission tomography (FDG-PET) imaging has rapidly become the standard of care for staging patients with lung cancer. We evaluated the prognostic value of metabolic tumor volume (MTV), a measure of tumor burden on FDG-PET imaging, in patients with non–small-cell lung cancer (NSCLC) treated definitively. A retrospective review identified 61 patients with NSCLC who underwent FDG-PET imaging for pretreatment staging. Metabolically active tumor regions were segmented on the PET scans semiautomatically to calculate the total body MTV. We determined the relationship of overall survival (OS) and progression-free survival (PFS) with MTV in the entire cohort, and in the subgroup treated definitively. The estimated median PFS and OS for the entire cohort were 11.1 months and 18.9 months. Higher MTV was significantly associated with worse OS (P = 0.00075) and PFS (P = 0.00077). For definitively treated patients, when MTV was analyzed as a binary value above or below the median value, 2-year PFS was 60% versus 39.7% (median PFS 34.9 vs. 11.9 months) and 2-year OS was 79.7% versus 33.3% (median OS 41.9 vs. 18.9 months), respectively (log-rank P = 0.12 for PFS and P = 0.066 for OS). When MTV was analyzed as a continuous variable, multivariate Cox proportional hazards analysis demonstrated a trend to worse PFS (hazard ratio [HR] = 1.31; P = 0.12) and significantly worse OS (HR = 1.53; P = 0.018) with increasing MTV after controlling for known prognostic variables. Tumor burden as assessed by MTV yields prognostic information on survival beyond that of established prognostic factors in patients with NSCLC treated definitively.
登录
查看更多内容
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者：
Thun, Michael J.
影响因子：
3.7
作者：
Chung, Man Ki;Jeong, Han-Sin;Baek, Chung-Hwan
通讯作者：
Baek, Chung-Hwan
DOI：
10.1016/j.ijrobp.2007.04.036
发表时间：
2007-10-01
影响因子：
7
作者：
Lee, Percy;Weerasuriya, Dilam K.;Loo, Billy W.
通讯作者：
Loo, Billy W.
影响因子：
254.7
作者：
Parkin, DM;Bray, F;Pisani, P
通讯作者：
Pisani, P
影响因子：
20.4
作者：
Goldstraw, Peter;Crowley, John;Sobin, Leslie
通讯作者：
Sobin, Leslie